Annexon, Inc.
ANNX
NASDAQ·Healthcare·Biotechnology·Mkt cap $797.9M
$4.87
▲ +0.62%
P/E
-4.20
Mkt Cap
$797.9M
52-Wk Range
$2.10–$7.18
52-Week Range
$2.10 - $7.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 120.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary C1q complement pathway targeting platform with deep mechanistic understanding
- Diversified pipeline with multiple clinical-stage candidates across high-value indications
- First-mover advantage in complement-mediated neurodegeneration treatment space
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase II/III advancement of ANX005 across multiple indications with large addressable markets
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-4.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ANNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 12, 2026
Reported EPS of -$0.28 vs -$0.24 consensus (-17.2% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-17.2%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 13, 2026
vs Industry
How ANNX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related